; and (B) for education of individuals diagnosed with rare kidney diseases on renal diet and lifestyle, genetic testing, and programs to promote urinalysis, and on mental and emotional health resources for families of rare kidney disease patients. (d) Research funded Research conducted using funds awarded through a cooperative agreement or grant under this section— (1) shall include study of genotype-phenotype relation to disease progression; and (2) with respect the populations studied in such research, may not include any consideration of quality-adjusted life years or disability adjusted life years, or other similar mechanisms that discriminate against individuals with disabilities in value and cost-effectiveness assessments. (e) Period of support; additional periods The period of support for a center of excellence under subsection (a) may not exceed 5 years, except that such period may be extended by the Director of the Institute for additional periods of not more than 5 years for each center if— (1) the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director of the Institute; and (2) such group has recommended to the Director of the Institute that such period should be extended. (f) Authorization of appropriations To carry out this section, there are authorized to be appropriated $6,000,000 for each of fiscal years 2024 through 2028. . 3. Understanding and Slowing the Progression of Rare Kidney Disease Through Early Intervention, Testing, and Treatment (a) In general The Secretary shall conduct a study on testing, preventative care, precision medicine, and treatment, with respect to rare kidney disease. Such study shall review— (1) the impact of routine urinalysis on the timely diagnosis of rare kidney disease and on the quality of patient care following a diagnosis of such disease; (2) the quality and reliability of kidney biopsy in the diagnosis of rare kidney disease